STOCK TITAN

QuidelOrtho Corporation (QDEL) Stock News, Oct 2021-Jan 2022

QDEL NASDAQ

QuidelOrtho Corporation reports developments in in vitro diagnostics, including rapid testing, immunoassay and molecular testing, clinical chemistry, transfusion medicine and point-of-care diagnostic platforms. Company updates commonly address financial results, revenue trends, guidance, respiratory testing seasonality, international market conditions and portfolio activity across labs, cardiac, immunohematology and molecular diagnostics.

Recurring news also covers product and technology developments such as the LEX VELO System, a point-of-care molecular PCR platform with FDA 510(k) clearance and CLIA waived status for Flu A, Flu B and COVID-19 testing, as well as diagnostic education topics including syphilis screening and high-sensitivity troponin. Governance and management changes appear alongside business updates and investor conference participation.

Rhea-AI Summary

Quidel Corporation (NASDAQ: QDEL) will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 1:30 p.m. Eastern time. Douglas Bryant, the CEO, will discuss the company's business and financial developments, followed by a Q&A session. A live webcast of the presentation will be available on Quidel's Investor Relations website, along with an audio archive for 14 days post-event. Quidel is a leader in rapid diagnostic testing solutions and aims to enhance global healthcare quality.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
conferences
-
Rhea-AI Summary

Quidel Corporation (NASDAQ: QDEL) reports its antigen tests, including QuickVue and Sofia, effectively detect the Omicron variant of COVID-19. CEO Douglas Bryant noted ongoing evaluations using live samples confirm prior findings from FDA RADx studies. Quidel is increasing production of its antigen tests to enhance community access. The company remains committed to monitoring COVID-19 variants to assure product efficacy. With over 40 years in diagnostics, Quidel continues to lead in rapid testing solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
none
-
Rhea-AI Summary

Quidel Corporation (NASDAQ: QDEL) has announced a definitive agreement to acquire Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX) for $24.68 per share, totaling approximately $6 billion. This acquisition, representing a 25% premium over Ortho's prior closing price, aims to enhance Quidel's diagnostic capabilities across over 130 countries. The transaction is expected to yield annual cost synergies of $90 million and revenue synergies exceeding $100 million by 2025, enhancing Quidel's product innovation and operational efficiency.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.35%
Tags
Rhea-AI Summary

Quidel Corporation (NASDAQ: QDEL) has secured a multi-year partnership with the Chicago Blackhawks to promote community health initiatives. This partnership features the donation of QuickVue At-Home OTC COVID-19 Tests to community partners, aiming to enhance healthcare access for local youth. The QuickVue test yields results in 10 minutes, demonstrating a proven accuracy of 83.5% for positive results and 99.2% for negative results. Additionally, the partnership includes marketing opportunities during games, reflecting Quidel's commitment to equitable healthcare.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
partnership
-
Rhea-AI Summary

Quidel has launched a series of infographics to educate Americans about Lyme disease, which affects nearly 480,000 individuals annually. The resources detail characteristics, warning signs, and areas of prevalence, emphasizing the importance of awareness for outdoor enthusiasts. Quidel's Sofia® 2 Lyme FIA test offers results within 15 minutes, a significant improvement over traditional testing methods. The infographics and additional educational content are available at LymeDiseaseAnswers.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
none
-
News
Rhea-AI Summary

Quidel Corporation (NASDAQ: QDEL) announced its ongoing commitment to monitor and detect COVID-19 variants, particularly the Omicron variant. CEO Douglas Bryant stated that their PCR assays can cover all known sequences of Omicron, ensuring detection through in silico analysis. The company is also ramping up its manufacturing capacity to produce 70 million tests monthly by year-end. These efforts aim to provide affordable testing solutions to communities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.94%
Tags
none
Rhea-AI Summary

Quidel Corporation (NASDAQ: QDEL) participated in the 33rd Annual Piper Sandler Healthcare Conference, discussing its business and financial developments. The virtual fireside chat's recording is accessible for 90 days via Quidel's website. With over 40 years in the medical device industry, Quidel has pioneered rapid diagnostic testing solutions for various diseases, including COVID-19. The company focuses on providing accurate and affordable testing globally, under trusted brands like Sofia® and QuickVue®.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.08%
Tags
none
-
Rhea-AI Summary

Quidel Corporation (NASDAQ: QDEL) reported strong financial results for Q3 2021, with total revenues of $509.7 million, a 7% increase from Q3 2020. Sales of COVID-19 products rose to $402.6 million, while influenza product sales grew to $13.8 million. GAAP EPS was $5.08, down from $5.33 in 2020. The company resolved litigation with Beckman Coulter, expecting annual cash payments between $70 million and $75 million. Quidel secured a $500 million agreement with the U.S. government for COVID-19 tests, and received CE Mark for its Savanna platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.05%
Tags
-
Rhea-AI Summary

Quidel Corporation (QDEL) has announced its sponsorship of the Distinguished Speaker Series by the Bay Area Lyme Foundation, aimed at enhancing public awareness and education about Lyme disease. The series features expert speakers discussing important topics related to Lyme disease. Quidel's Sofia® 2 Lyme FIA test offers rapid diagnostic results, providing vital information within 15 minutes. This initiative supports the rising number of Lyme disease cases expected to reach 476,000 in the U.S. by year-end, promoting easier diagnosis and treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.20%
Tags
none
Rhea-AI Summary

Quidel Corporation (NASDAQ: QDEL), a leader in rapid diagnostic testing, will announce its fiscal Q3 2021 financial results on November 4, 2021, post-market. A conference call will follow at 5:00 p.m. ET to discuss results and provide updates on business trends. Quidel is recognized for its innovative testing solutions, including the first FDA-cleared rapid tests for influenza and SARS-CoV-2. The company aims to enhance healthcare quality globally through its diverse product portfolio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.20%
Tags
conferences earnings date

FAQ

What is the current stock price of QuidelOrtho (QDEL)?

QuidelOrtho (QDEL) last closed at $8.92.

What is the market cap of QuidelOrtho (QDEL)?

The market cap of QuidelOrtho (QDEL) is approximately $612.0M.